Free Trial

VolitionRx (VNRX) Competitors

VolitionRx logo
$0.75 +0.02 (+2.70%)
Closing price 04:00 PM Eastern
Extended Trading
$0.74 -0.01 (-1.33%)
As of 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VNRX vs. NGNE, CAPR, RNAC, OLMA, ADCT, NMRA, OCGN, HRTX, KOD, and CRVS

Should you be buying VolitionRx stock or one of its competitors? The main competitors of VolitionRx include Neurogene (NGNE), Capricor Therapeutics (CAPR), Cartesian Therapeutics (RNAC), Olema Pharmaceuticals (OLMA), ADC Therapeutics (ADCT), Neumora Therapeutics (NMRA), Ocugen (OCGN), Heron Therapeutics (HRTX), Kodiak Sciences (KOD), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry.

VolitionRx vs. Its Competitors

Neurogene (NASDAQ:NGNE) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

In the previous week, Neurogene had 1 more articles in the media than VolitionRx. MarketBeat recorded 2 mentions for Neurogene and 1 mentions for VolitionRx. Neurogene's average media sentiment score of 1.82 beat VolitionRx's score of 0.00 indicating that Neurogene is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neurogene
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
VolitionRx
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

VolitionRx has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurogene$930K348.37-$75.14M-$4.35-5.22
VolitionRx$1.31M59.61-$35.32M-$0.27-2.78

Neurogene has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.

52.4% of Neurogene shares are held by institutional investors. Comparatively, 8.1% of VolitionRx shares are held by institutional investors. 11.6% of Neurogene shares are held by insiders. Comparatively, 10.4% of VolitionRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Neurogene has a net margin of 0.00% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat Neurogene's return on equity.

Company Net Margins Return on Equity Return on Assets
NeurogeneN/A -36.16% -32.51%
VolitionRx -2,321.14%N/A -163.39%

Neurogene presently has a consensus target price of $46.17, suggesting a potential upside of 103.20%. VolitionRx has a consensus target price of $3.50, suggesting a potential upside of 366.67%. Given VolitionRx's stronger consensus rating and higher probable upside, analysts clearly believe VolitionRx is more favorable than Neurogene.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neurogene
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75
VolitionRx
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.00

Summary

Neurogene beats VolitionRx on 9 of the 16 factors compared between the two stocks.

Get VolitionRx News Delivered to You Automatically

Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VNRX vs. The Competition

MetricVolitionRxDiagnostic substances IndustryMedical SectorNYSE Exchange
Market Cap$77.99M$19.95M$5.70B$21.12B
Dividend YieldN/AN/A4.69%3.60%
P/E Ratio-2.08N/A21.1927.40
Price / Sales59.6122.04461.3060.38
Price / CashN/AN/A36.2222.92
Price / Book-6.820.028.664.69
Net Income-$35.32M-$15.34M$3.25B$995.51M
7 Day Performance11.11%11.11%4.20%1.64%
1 Month Performance-1.32%-3.45%10.82%5.92%
1 Year Performance8.70%-42.10%34.70%11.50%

VolitionRx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VNRX
VolitionRx
1.5738 of 5 stars
$0.75
+2.7%
$3.50
+366.7%
-1.9%$77.99M$1.31M-2.0880
NGNE
Neurogene
3.5589 of 5 stars
$21.66
-3.0%
$46.17
+113.1%
-46.6%$318.61M$930K-4.9890
CAPR
Capricor Therapeutics
2.5455 of 5 stars
$6.27
-8.9%
$22.56
+259.7%
+42.4%$314.26M$22.27M-4.42101Trending News
Gap Up
RNAC
Cartesian Therapeutics
2.3073 of 5 stars
$12.05
+1.8%
$40.00
+232.0%
-18.0%$307.30M$38.91M-0.2364News Coverage
Positive News
OLMA
Olema Pharmaceuticals
2.4092 of 5 stars
$4.59
+4.1%
$24.50
+433.8%
-69.2%$301.74MN/A-2.2870Positive News
ADCT
ADC Therapeutics
1.2397 of 5 stars
$3.14
+3.6%
$7.75
+146.8%
-13.4%$300.51M$70.84M-2.17310
NMRA
Neumora Therapeutics
2.4266 of 5 stars
$1.96
+5.9%
$7.14
+264.4%
-80.8%$299.23MN/A-1.22108Gap Up
OCGN
Ocugen
1.2046 of 5 stars
$1.01
-1.0%
$6.00
+494.1%
-30.0%$297.87M$4.05M-5.3280Upcoming Earnings
HRTX
Heron Therapeutics
3.8025 of 5 stars
$1.92
-0.5%
$5.00
+160.4%
-39.7%$294.45M$144.29M-32.00300
KOD
Kodiak Sciences
2.5305 of 5 stars
$5.08
-8.0%
$9.00
+77.2%
+173.2%$291.26MN/A-1.4090
CRVS
Corvus Pharmaceuticals
2.6818 of 5 stars
$4.45
+4.5%
$15.00
+237.1%
+118.9%$290.74MN/A-4.5430

Related Companies and Tools


This page (NYSE:VNRX) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners